Stock Buybacks (Quarterly) Chart

View Stock Buybacks (Quarterly) for AKBA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Stock Buybacks (Quarterly) Chart
Start Trial

Historical Stock Buybacks (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -3.325M
March 31, 2026 -0.151M
December 31, 2025 -0.063M
September 30, 2025 -1.113M
June 30, 2025 -1.72M
March 31, 2025 -65.47M
December 31, 2024 -22.32M
September 30, 2024 -1.745M
June 30, 2024 -0.014M
March 31, 2024 -18.95M
December 31, 2023 -6.71M
September 30, 2023 -0.05M
June 30, 2023 0.00
March 31, 2023 -0.034M
December 31, 2022 0.001M
September 30, 2022 -0.063M
June 30, 2022 0.009M
March 31, 2022 -7.545M
December 31, 2021 -5.403M
September 30, 2021 -16.48M
June 30, 2021 -37.37M
March 31, 2021 -29.69M
December 31, 2020 -10.54M
September 30, 2020 -1.054M
June 30, 2020 -142.81M
Date Value
March 31, 2020 -57.35M
December 31, 2019 -16.75M
September 30, 2019 -0.195M
June 30, 2019 -9.23M
March 31, 2019 -0.553M
December 31, 2018 -0.091M
September 30, 2018 -0.361M
June 30, 2018 -0.217M
March 31, 2018 -95.91M
December 31, 2017 -5.244M
September 30, 2017 -63.79M
June 30, 2017 -45.47M
March 31, 2017 -1.748M
December 31, 2016 -3.53M
September 30, 2016 -2.342M
June 30, 2016 0.091M
March 31, 2016 -61.18M
December 31, 2015 -4.342M
September 30, 2015 -13.95M
June 30, 2015 -64.76M
March 31, 2015 -0.05M
December 31, 2014 -0.189M
September 30, 2014 10.72M
June 30, 2014 -9.179M
March 31, 2014 -105.75M

Stock Buyback Definition

Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.

Read full definition.

Stock Buybacks (Quarterly) Range, Past 5 Years

View Stock Buybacks (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Stock Buybacks (Quarterly) Benchmarks

View Stock Buybacks (Quarterly) Benchmarks
Start Trial
Emergent BioSolutions, Inc. 8.00M
Exelixis, Inc. 307.53M
ADMA Biologics, Inc. 25.02M
Arcutis Biotherapeutics, Inc. -2.99M
Relay Therapeutics, Inc. -323.74M